炎症性皮肤病与关节病患者在COVID-19疫情期间的防护行为因治疗类型而异:一项横断面患者调查
结论提示靶向治疗患者更严格的防护行为可能部分解释其较少的COVID-19不良结局。
要点
- 接受靶向治疗(生物制剂/JAK抑制剂)的IMID患者更可能采取严格防护行为。
- 防护行为与已知重症COVID-19危险因素(男性、肥胖、共病负担)及焦虑抑郁相关。
- 不同国家间防护行为比例存在适度差异,需基于证据的患者沟通。
核心结论
- 接受靶向治疗的IMID患者更严格的防护行为可能部分解释其报告较低的COVID-19不良结局风险。
研究设计与样本
- 2020年5月4日至9月7日开展的在线横断面调查,纳入全球银屑病患者及英国风湿与肌肉骨骼疾病患者。
- 共3720例参与者(2869例银屑病,851例RMD),来自74个国家。
- 采用多因素logistic回归评估治疗类型与防护行为的关联,并调整临床和人口学特征。
临床怎么用
- 临床中应认识到接受靶向治疗的IMID患者可能因更严格的防护行为而减少感染暴露风险。
- 需基于证据向患者沟通风险防护策略,尤其关注男性、肥胖、共病负担及焦虑抑郁筛查阳性者。
- 不同治疗组、疾病类型和国家间的防护行为差异可为公共卫生指南更新提供参考。
局限性
- 横断面设计无法推断因果关系。
- 研究基于在线调查,可能存在选择偏倚和信息偏倚。
- 银屑病为全球范围而RMD仅限英国,疾病样本来源不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatments. OBJECTIVES: We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation. METHODS: Online surveys were completed by individuals with psoriasis (globally) or rheumatic and musculoskeletal diseases (RMDs) (UK only) between 4 May and 7 September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical and demographic characteristics. We characterized international variation in a mixed-effects model. RESULTS: Of 3720 participants (2869 psoriasis, 851 RMDs) from 74 countries, 2262 (60·8%) reported the most stringent risk-mitigating behaviour (classified here under the umbrella term 'shielding'). A greater proportion of those receiving targeted therapies (biologics and Janus Kinase inhibitors) reported shielding compared with those receiving no systemic therapy [adjusted odds ratio (OR) 1·63, 95% confidence interval (CI) 1·35-1·97]. The association between targeted therapy and shielding was preserved when standard systemic therapy was used as the reference group (OR 1·39, 95% CI 1·23-1·56). Shielding was associated with established risk factors for severe COVID-19 [male sex (OR 1·14, 95% CI 1·05-1·24), obesity (OR 1·37, 95% CI 1·23-1·54), comorbidity burden (OR 1·43, 95% CI 1·15-1·78)], a primary indication of RMDs (OR 1·37, 95% CI 1·27-1·48) and a positive anxiety or depression screen (OR 1·57, 95% CI 1·36-1·80). Modest differences in the proportion shielding were observed across nations. CONCLUSIONS: Greater risk-mitigating behaviour among people with IMIDs receiving targeted therapies may contribute to the reported lower risk of adverse COVID-19 outcomes. The behaviour variation across treatment groups, IMIDs and nations reinforces the need for clear evidence-based patient communication on risk-mitigation strategies and may help inform updated public health guidelines as the pandemic continues.
引用
- Mahil SK, Yates M, Langan SM, et al. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. Br J Dermatol. 2021. PMID: 33368145. doi:10.1111/bjd.19755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。